Liver Carcinoma Clinical Trial
Official title:
Analysis of Body Composition by Bioelectrical Impedance in Patients With Hepatocellular Carcinoma (HCC) Undergoing Treatment Radioablation
Number of shows: 20 patients Track: A month with three visiting Intervention: Nutritional assessment including anthropometry, bioelectrical impedance, biochemical tests, Psychometric Hepatic Encephalopathy Score and Critical Flicker Frequency.
There will be a prospective, longitudinal, comparative. It included 20 patients diagnosed
with hepatocellular carcinoma. As there are a finite number of active patients at the
institute, and no studies with sample size well established, has seen a sample size of 20
patients.
The duration of individual monitoring shall be one month to three visits (baseline, week 2
and week 4 after receiving the first radiofrequency ablation). Each visit will be a
nutritional assessment including anthropometry, bioelectrical impedance, biochemical tests,
Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF).
Anthropometric measures to be taken are weight, height and arm circumference average.
Bioelectrical impedance will be using a single frequency impedance meter (425 to -50 KHz,
Range 0 to 10,000) Bioelectrical Body Composition Analyzer Quantium II RJL Systems. The team
measured the subjects' impedance, resistance, reactance and phase angle by Lean Body program
provided by the manufacturer.
Hepatic encephalopathy be evaluated by testing PHES and was measured CFF, also also be
measured ammonium, tumor necrosis factor, IL-1, IL-6, IL-10, renin angiotensin aldosterone.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04443322 -
Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )
|
N/A | |
| Completed |
NCT02305459 -
CIRSE Registry for SIR-Spheres Therapy
|
||
| Terminated |
NCT00791544 -
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Completed |
NCT02424955 -
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
|
N/A | |
| Completed |
NCT03775863 -
AFP Model and Liver Transplantation.
|
||
| Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
| Recruiting |
NCT06144385 -
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT01717729 -
Hepatocellular Carcinoma Treated With Iodine-125 Implantation
|
Phase 3 | |
| Completed |
NCT03178409 -
Combined HCC-MFCCC
|
N/A | |
| Suspended |
NCT04955808 -
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
|
||
| Recruiting |
NCT01380392 -
The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT01482442 -
SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01272557 -
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
|
Phase 2 | |
| Completed |
NCT00328770 -
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
|
Phase 2/Phase 3 | |
| Completed |
NCT05681234 -
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
|
N/A | |
| Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
| Active, not recruiting |
NCT02465060 -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
|
Phase 2 | |
| Recruiting |
NCT04288323 -
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis
|
Phase 4 |